The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Witty’s departure was unexpected, but follows a downturn in the healthcare company’s financial outlook. He will be replaced ...

Having now appointed Henry Gosebruch as CEO of the intact company, Galapagos says its priorities are exploring strategic ...

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...

The mass cuts, which included communications staff, could slow public notices on medical device recalls and other safety ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...